Medifast Reports Steep Revenue Decline Amid GLP-1 Pressure, Reinstates Guidance
Event summary
- Q4 2025 revenue dropped 36.9% YoY to $75.1M, driven by a 40.6% decline in active earning coaches to 16,100.
- Full-year 2025 revenue fell 36% to $385.8M, with a net loss of $18.7M, including a $12.1M non-cash tax provision.
- Revenue per active coach rose 6.2% YoY to $4,664, signaling improved productivity.
- Medifast reinstated annual guidance, targeting $270M–$300M in 2026 revenue but projecting continued losses.
- Cash position strengthened to $167.3M with no debt as of December 31, 2025.
The big picture
Medifast's results reflect broader industry disruption from GLP-1 weight loss drugs, compounding its struggles with client acquisition. The company's reinstated guidance suggests cautious optimism about its metabolic health strategy, but sustained losses and coach network contraction highlight execution risks. With a strong cash position, Medifast has financial flexibility to navigate the transition, though competitive pressures remain intense.
What we're watching
- GLP-1 Competition
- Whether Medifast can mitigate client acquisition challenges from rapid GLP-1 adoption.
- Coach Network Dynamics
- The pace at which coach productivity improvements translate to revenue growth.
- Metabolic Health Pivot
- How effectively Medifast executes its shift toward metabolic health as a differentiator.